

Angela Pirillo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3807539/publications.pdf>

Version: 2024-02-01

109
papers

5,502
citations

117625

34
h-index

85541

71
g-index

110
all docs

110
docs citations

110
times ranked

8045
citing authors

#	ARTICLE	IF	CITATIONS
1	LOX-1, OxLDL, and Atherosclerosis. <i>Mediators of Inflammation</i> , 2013, 2013, 1-12.	3.0	548
2	High-Density Lipoprotein Subfractions - What the Clinicians Need to Know. <i>Cardiology</i> , 2013, 124, 116-125.	1.4	509
3	Global epidemiology of dyslipidaemias. <i>Nature Reviews Cardiology</i> , 2021, 18, 689-700.	13.7	290
4	HDL in innate and adaptive immunity. <i>Cardiovascular Research</i> , 2014, 103, 372-383.	3.8	236
5	Berberine, a plant alkaloid with lipid- and glucose-lowering properties: From in vitro evidence to clinical studies. <i>Atherosclerosis</i> , 2015, 243, 449-461.	0.8	231
6	Dietary linoleic acid and human health: Focus on cardiovascular and cardiometabolic effects. <i>Atherosclerosis</i> , 2020, 292, 90-98.	0.8	213
7	Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. <i>Atherosclerosis</i> , 2012, 220, 381-386.	0.8	212
8	Emerging role of high density lipoproteins as a player in the immune system. <i>Atherosclerosis</i> , 2012, 220, 11-21.	0.8	158
9	HDL in Infectious Diseases and Sepsis. <i>Handbook of Experimental Pharmacology</i> , 2015, 224, 483-508.	1.8	145
10	Apolipoprotein C-III: From Pathophysiology to Pharmacology. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 675-687.	8.7	144
11	Long Pentraxin 3, a Key Component of Innate Immunity, Is Modulated by High-Density Lipoproteins in Endothelial Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 925-931.	2.4	137
12	Anti-inflammatory and anti-atherogenic effects of catechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. <i>Atherosclerosis</i> , 2007, 191, 265-271.	0.8	131
13	Effector Memory T cells Are Associated With Atherosclerosis in Humans and Animal Models. <i>Journal of the American Heart Association</i> , 2012, 1, 27-41.	3.7	114
14	Statin use and risk of new-onset diabetes: A meta-analysis of observational studies. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 396-406.	2.6	111
15	Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering. <i>Cardiovascular Research</i> , 2016, 112, 429-442.	3.8	105
16	Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials. <i>British Journal of Pharmacology</i> , 2017, 174, 3973-3985.	5.4	105
17	Postprandial lipemia as a cardiometabolic risk factor. <i>Current Medical Research and Opinion</i> , 2014, 30, 1489-1503.	1.9	94
18	Proteome of endothelial cell-derived procoagulant microparticles. <i>Proteomics</i> , 2005, 5, 4443-4455.	2.2	85

#	ARTICLE	IF	CITATIONS
19	Cholesterol metabolism, pancreatic β -cell function and diabetes. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 2149-2156.	3.8	76
20	Modified HDL: Biological and physiopathological consequences. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2006, 16, 371-386.	2.6	75
21	The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis. <i>Current Atherosclerosis Reports</i> , 2018, 20, 12.	4.8	67
22	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. <i>Atherosclerosis Supplements</i> , 2017, 29, 17-24.	1.2	65
23	Biological Consequences of Dysfunctional HDL. <i>Current Medicinal Chemistry</i> , 2019, 26, 1644-1664.	2.4	65
24	Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies. <i>Cardiovascular Research</i> , 2019, 115, 510-518.	3.8	63
25	Soluble Lectin-Like Oxidized Low Density Lipoprotein Receptor-1 as a Biochemical Marker for Atherosclerosis-Related Diseases. <i>Disease Markers</i> , 2013, 35, 413-418.	1.3	60
26	Inhibition of acyl-CoA: cholesterol acyltransferase decreases apolipoprotein B-100-containing lipoprotein secretion from HepG2 cells. <i>Journal of Lipid Research</i> , 1996, 37, 1-14.	4.2	60
27	Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL. <i>Cardiovascular Research</i> , 2003, 59, 169-180.	3.8	59
28	Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization. <i>British Journal of Haematology</i> , 2004, 127, 97-104.	2.5	53
29	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. <i>Atherosclerosis</i> , 2018, 277, 413-418.	0.8	48
30	HDLs, immunity, and atherosclerosis. <i>Current Opinion in Lipidology</i> , 2011, 22, 410-416.	2.7	41
31	New Pharmacological Approaches to Target PCSK9. <i>Current Atherosclerosis Reports</i> , 2020, 22, 24.	4.8	41
32	Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 751-759.	2.6	39
33	Macrophage metalloproteinases degrade high-density-lipoprotein-associated apolipoprotein A-I at both the N- and C-termini. <i>Biochemical Journal</i> , 2002, 362, 627-634.	3.7	37
34	Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) by 15-lipoxygenase-modified LDL in endothelial cells. <i>Atherosclerosis</i> , 2011, 214, 331-337.	0.8	36
35	Oxidized LDL induce hsp70 expression in human smooth muscle cells. <i>FEBS Letters</i> , 1995, 372, 1-5.	2.8	34
36	15-Lipoxygenase-mediated modification of high-density lipoproteins impairs SR-BI- and ABCA1-dependent cholesterol efflux from macrophages. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2006, 1761, 292-300.	2.4	34

#	ARTICLE	IF	CITATIONS
37	Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: The heredity survey. <i>International Journal of Cardiology</i> , 2018, 252, 193-198.	1.7	34
38	Impact of protein glycosylation on lipoprotein metabolism and atherosclerosis. <i>Cardiovascular Research</i> , 2021, 117, 1033-1045.	3.8	33
39	Omega-3 polyunsaturated fatty acids in the treatment of hypertriglyceridaemia. <i>International Journal of Cardiology</i> , 2013, 170, S16-S20.	1.7	32
40	Statin Intolerance: Diagnosis and Remedies. <i>Current Cardiology Reports</i> , 2015, 17, 27.	2.9	32
41	The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion. <i>Atherosclerosis Supplements</i> , 2019, 39, e1-e8.	1.2	31
42	Simvastatin Modulates the Heat Shock Response and Cytotoxicity Mediated by Oxidized LDL in Cultured Human Endothelial Smooth Muscle Cells. <i>Biochemical and Biophysical Research Communications</i> , 1997, 231, 437-441.	2.1	30
43	Human Endothelial Cells Exposed to Oxidized LDL Express hsp70 Only When Proliferating. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 1104-1111.	2.4	29
44	Niemann-Pick C1-Like 1 (NPC1L1) Inhibition and Cardiovascular Diseases. <i>Current Medicinal Chemistry</i> , 2016, 23, 983-999.	2.4	29
45	Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia. <i>Atherosclerosis Supplements</i> , 2013, 14, 237-242.	1.2	27
46	Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality. <i>Current Pharmaceutical Design</i> , 2013, 19, 3841-3857.	1.9	27
47	In vitro isolation of circulating endothelial progenitor cells is related to the high density lipoprotein plasma levels. <i>International Journal of Molecular Medicine</i> , 2006, 17, 203-8.	4.0	27
48	Macrophage metalloproteinases degrade high-density-lipoprotein-associated apolipoprotein A-I at both the N- and C-termini. <i>Biochemical Journal</i> , 2002, 362, 627.	3.7	25
49	Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials. <i>Pharmacological Research</i> , 2019, 143, 143-150.	7.1	25
50	The 15-Lipoxygenase-Modified High Density Lipoproteins 3 Fail to Inhibit the TNF- α -Induced Inflammatory Response in Human Endothelial Cells. <i>Journal of Immunology</i> , 2008, 181, 2821-2830.	0.8	24
51	Upregulation of lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) expression in human endothelial cells by modified high density lipoproteins. <i>Biochemical and Biophysical Research Communications</i> , 2012, 428, 230-233.	2.1	23
52	Effect of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 341-346.	1.9	23
53	Multilevel Models to Estimate Carotid Intima-Media Thickness Curves for Individual Cardiovascular Risk Evaluation. <i>Stroke</i> , 2019, 50, 1758-1765.	2.0	23
54	HDL in Immune-Inflammatory Responses: Implications beyond Cardiovascular Diseases. <i>Cells</i> , 2021, 10, 1061.	4.1	23

#	ARTICLE	IF	CITATIONS
55	Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project. <i>Atherosclerosis Supplements</i> , 2020, 42, e49-e58.	1.2	23
56	Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors. <i>Current Atherosclerosis Reports</i> , 2021, 23, 79.	4.8	23
57	Constituents of <i>Nothapodytes foetida</i> . <i>Journal of the Chemical Society Perkin Transactions 1</i> , 1995, , 583.	0.9	22
58	Association between OLR1 K167N SNP and Intima Media Thickness of the Common Carotid Artery in the General Population. <i>PLoS ONE</i> , 2012, 7, e31086.	2.5	21
59	Pitavastatin and HDL: Effects on plasma levels and function(s). <i>Atherosclerosis Supplements</i> , 2017, 27, e1-e9.	1.2	21
60	Overexpression of Inducible Heat Shock Protein 70 in COS-1 Cells Fails to Protect From Cytotoxicity of Oxidized LDLs. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 348-354.	2.4	18
61	Modification of HDL3 by mild oxidative stress increases ATP-binding cassette transporter 1-mediated cholesterol efflux. <i>Cardiovascular Research</i> , 2007, 75, 566-574.	3.8	18
62	Cholesterol membrane content has a ubiquitous evolutionary function in immune cell activation: the role of HDL. <i>Current Opinion in Lipidology</i> , 2019, 30, 462-469.	2.7	18
63	Oxidized Lipoproteins and Endothelium. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000, 38, 155-60.	2.3	16
64	Native LDL and Oxidized LDL modulate cyclooxygenase-2 expression in HUVECs through a p38-MAPK, NF- κ B, CRE dependent pathway and affect PGE2 synthesis. <i>International Journal of Molecular Medicine</i> , 2004, 14, 353-9.	4.0	15
65	Statins prevent tissue factor induction by protease-activated receptors 1 and 2 in human umbilical vein endothelial cells in vitro. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1608-1619.	3.8	15
66	Prevalence of classical CD14 ⁺⁺ /CD16 ⁺ but not of intermediate CD14 ⁺⁺ /CD16 ⁺ monocytes in hypoalphalipoproteinemia. <i>International Journal of Cardiology</i> , 2013, 168, 2886-2889.	1.7	15
67	Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives. <i>Vascular Health and Risk Management</i> , 2017, Volume 13, 343-351.	2.3	14
68	Statins increase Lp(a) plasma level: is this clinically relevant?. <i>European Heart Journal</i> , 2020, 41, 2285-2287.	2.2	14
69	Enhanced Macrophage Uptake of Elastase-Modified High-Density Lipoproteins. <i>Biochemical and Biophysical Research Communications</i> , 2000, 271, 386-391.	2.1	13
70	HDL: To Treat or Not To Treat?. <i>Current Atherosclerosis Reports</i> , 2014, 16, 429.	4.8	12
71	Update on the management of severe hypertriglyceridemia – focus on free fatty acid forms of omega-3. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2129.	4.3	12
72	Twelve Variants Polygenic Score for Low-Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations. <i>Journal of the American Heart Association</i> , 2022, 11, e023668.	3.7	12

#	ARTICLE	IF	CITATIONS
73	Oxysterols from oxidized LDL are cytotoxic but fail to induce hsp70 expression in endothelial cells. <i>FEBS Letters</i> , 1999, 462, 113-116.	2.8	11
74	New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2022, 29, 161-166.	2.3	11
75	Dual effect of hypochlorite in the modification of high density lipoproteins. <i>Biochemical and Biophysical Research Communications</i> , 2010, 403, 447-451.	2.1	10
76	PCSK9 inhibition and Lp(a) reduction: another piece of the puzzle?. <i>European Heart Journal</i> , 2018, 39, 2586-2588.	2.2	10
77	Omega-3 for Cardiovascular Diseases: Where Do We Stand After REDUCE-IT and STRENGTH?. <i>Circulation</i> , 2021, 144, 183-185.	1.6	10
78	15 α -Lipoxygenase-Mediated Modification of HDL ³ Impairs eNOS Activation in Human Endothelial Cells. <i>Lipids</i> , 2014, 49, 317-326.	1.7	9
79	Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction. <i>Current Atherosclerosis Reports</i> , 2020, 22, 74.	4.8	9
80	Predictive value of HDL function in patients with coronary artery disease: relationship with coronary plaque characteristics and clinical events. <i>Annals of Medicine</i> , 2022, 54, 1036-1046.	3.8	9
81	Beyond LDL-C levels, does remnant cholesterol estimation matter?. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1088-1090.	1.8	8
82	LDL-Cholesterol-Lowering Therapy. <i>Handbook of Experimental Pharmacology</i> , 2020, , 1.	1.8	8
83	Improving lipid management in patients with acute coronary syndrome: The ACS Lipid EuroPath tool. <i>Atherosclerosis Supplements</i> , 2020, 42, e65-e71.	1.2	8
84	Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives. <i>Atherosclerosis Supplements</i> , 2020, 42, e59-e64.	1.2	8
85	Recent insights into low-density lipoprotein metabolism and therapy. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2021, 24, 120-126.	2.5	7
86	Insights from ORION studies: focus on inclisiran safety. <i>Cardiovascular Research</i> , 2021, 117, 24-26.	3.8	6
87	Hypercholesterolemia and cardiovascular disease: Focus on high cardiovascular risk patients. <i>Atherosclerosis Supplements</i> , 2020, 42, e30-e34.	1.2	6
88	Proprotein Convertase Subtilisin Kexin 9 Inhibitors. <i>Cardiology Clinics</i> , 2018, 36, 241-256.	2.2	5
89	Increasing high-density lipoprotein cholesterol levels for cardiovascular benefit: The end of a dream?. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 531-532.	1.8	5
90	Worldwide Changes in Total Cholesterol and Non-HDL-Cholesterol Trends Indicate Where the Challenges Are for the Coming Years. <i>Clinical Chemistry</i> , 2021, 67, 30-32.	3.2	5

#	ARTICLE	IF	CITATIONS
91	Similarities and differences between European and American guidelines on the management of blood lipids to reduce cardiovascular risk. <i>Atherosclerosis Supplements</i> , 2020, 42, e1-e5.	1.2	5
92	Genetically determined hypercholesterolaemia results into premature leucocyte telomere length shortening and reduced haematopoietic precursors. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 721-729.	1.8	5
93	Statin use and risk of new-onset diabetes: a meta-analysis of observational studies. <i>Atherosclerosis</i> , 2017, 263, e262-e263.	0.8	4
94	Lipoprotein remnants: to be or not to be. <i>European Heart Journal</i> , 2021, 42, 4844-4846.	2.2	4
95	High-density lipoprotein cholesterol levels, cardiovascular disease risk, and cancer: a relation which does not apply to all?. <i>Cardiovascular Research</i> , 2019, 115, 6-7.	3.8	3
96	The cardiovascular benefit of Lp(a) reduction: not there yet. <i>European Heart Journal</i> , 2020, 41, 4256-4258.	2.2	3
97	Oxidized lipoproteins induce long-lasting inhibition of nitric oxide synthase from a murine endothelioma cell line (bEnd.4). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1995, 2, 123-130.	1.5	2
98	Production and Metabolism of Triglyceride-Rich Lipoproteins in Both the Normal and Diabetic States. <i>Contemporary Diabetes</i> , 2014, , 125-139.	0.0	2
99	Strategies for the use of nonstatin therapies. <i>Current Opinion in Lipidology</i> , 2017, 28, 458-464.	2.7	2
100	Understanding the efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 829-831.	1.8	2
101	Therapy and clinical trials. <i>Current Opinion in Lipidology</i> , 2011, 22, 324-325.	2.7	1
102	Targeting Cholesterol in Non-ischemic Heart Failure: A Role for LDLR Gene Therapy?. <i>Molecular Therapy</i> , 2017, 25, 2435-2437.	8.2	1
103	Lipid Lowering and Incidence of Cataract, a Role for Fibrates. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 318-319.	4.7	1
104	Hypercholesterolemia and cardiovascular disease: What to do before initiating pharmacological therapy. <i>Atherosclerosis Supplements</i> , 2020, 42, e25-e29.	1.2	1
105	3.P.87 Two distinct components of oxidized LDL mediate the heat shock response and cytotoxicity triggered by OxLDL. <i>Atherosclerosis</i> , 1997, 134, 216-217.	0.8	0
106	Effect of PCSK9 loss-of-function mutation R46I on plasma lipids, endothelial function and vascular inflammation in the post-prandial state. <i>Atherosclerosis</i> , 2017, 263, e136.	0.8	0
107	PCSK9 inhibition in statin-intolerant HeFH patients: What's new?. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1525-1527.	1.8	0
108	The Challenge of Lipid Management in Patients with Diabetes or Other Endocrine Disorders. <i>European Endocrinology</i> , 2010, 7, 92.	1.5	0

#	ARTICLE	IF	CITATIONS
109	Oxidized Ldl Trigger the Expression of Hsp70 in Cultured Endothelial Cells. Medical Science Symposia Series, 1996, , 603-612.	0.0	0